perphenazine has been researched along with Anochlesia in 21 studies
Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.
perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The advantages of BL-1020 for treatment of schizophrenia stem from its being a DA/5HT antagonist and a GABAergic agonist that releases cortical DA and antagonizes amphetamine-induced hyperactivity with reduced catalepsy and sedation." | 3.75 | BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia. ( Geffen, Y; Gil-Ad, I; Huang, M; Klapper, L; Meltzer, HY; Nudelman, A; Rephaeli, A; Savitsky, K; Weizman, A; Winkler, I, 2009) |
| "When quercetin was combined with a subthreshold dose of L-dopa plus carbidopa, the anticatatonic effect was potentiated." | 1.32 | Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition. ( Kulkarni, SK; Naidu, PS; Singh, A, 2003) |
| " On chronic administration (once daily for 21 days) losartan failed to block apomorphine-induced hyperlocomotion, but the inhibition of stereotypic response and potentiation of neuroleptic-induced catalepsy remained unaltered." | 1.30 | Modulation of motor functions involving the dopaminergic system by AT1 receptor antagonist, losartan. ( Chopra, K; Kulkarni, SK; Raghavendra, V, 1998) |
| "Perphenazine (5 mg/kg) produced severe catalepsy which lasted for more than 4 hr." | 1.27 | Yohimbine potentiates the anticataleptic action of clonidine against perphenazine-induced catalepsy in rats. ( Garg, SK; Kulkarni, SK; Shukla, VK, 1986) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 15 (71.43) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 3 (14.29) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nudelman, A | 2 |
| Gil-Ad, I | 2 |
| Shpaisman, N | 1 |
| Terasenko, I | 1 |
| Ron, H | 1 |
| Savitsky, K | 2 |
| Geffen, Y | 2 |
| Weizman, A | 2 |
| Rephaeli, A | 2 |
| Huang, M | 1 |
| Klapper, L | 1 |
| Winkler, I | 1 |
| Meltzer, HY | 1 |
| Singh, A | 1 |
| Naidu, PS | 1 |
| Kulkarni, SK | 6 |
| BERRY, RV | 1 |
| KAMIN, SH | 1 |
| KLINE, A | 1 |
| Irwin, S | 1 |
| Stille, G | 1 |
| Verma, A | 2 |
| Raghavendra, V | 1 |
| Chopra, K | 1 |
| Shukla, VK | 2 |
| Garg, SK | 2 |
| Tikal, K | 1 |
| Costall, B | 1 |
| Naylor, RJ | 1 |
| Delini-Stula, A | 1 |
| Uno, M | 1 |
| Ueki, S | 1 |
| Ogawa, N | 1 |
| Watanabe, S | 1 |
| Gomita, Y | 1 |
| Araki, Y | 1 |
| Sharma, VN | 1 |
| Mital, RL | 1 |
| Banerjee, SP | 1 |
| Sharma, HL | 1 |
| Loew, DM | 1 |
| Niemegeers, CJ | 1 |
| Verbruggen, FJ | 1 |
| Janssen, PA | 1 |
| Fog, R | 1 |
| Randrup, A | 1 |
| Pakkenberg, H | 1 |
| Morpurgo, C | 1 |
| Theobald, W | 1 |
21 other studies available for perphenazine and Anochlesia
| Article | Year |
|---|---|
A mutual prodrug ester of GABA and perphenazine exhibits antischizophrenic efficacy with diminished extrapyramidal effects.
Topics: Administration, Oral; Animals; Antipsychotic Agents; Biological Availability; Catalepsy; Dextroamphe | 2008 |
BL-1020: a novel antipsychotic drug with GABAergic activity and low catalepsy, is efficacious in a rat model of schizophrenia.
Topics: Acetylcholine; Amphetamine; Animals; Antipsychotic Agents; Biological Availability; Brain; Catalepsy | 2009 |
Quercetin potentiates L-Dopa reversal of drug-induced catalepsy in rats: possible COMT/MAO inhibition.
Topics: Animals; Antiparkinson Agents; Catalepsy; Catechol O-Methyltransferase Inhibitors; Levodopa; Male; M | 2003 |
An unusual complication following the use of trilafon in children.
Topics: Catalepsy; Child; Infant; Perphenazine; Phenothiazines | 1958 |
Considerations for the pre-clinical evaluation of new psychiatric drugs: a case study with phenothiazine-like tranquilizers.
Topics: Aggression; Animals; Ataxia; Behavior, Animal; Catalepsy; Emotions; Extrapyramidal Tracts; Fear; Flu | 1966 |
[Arousal inhibiting and catalepsy in neuroleptic drugs].
Topics: Animals; Arousal; Catalepsy; Chlorpromazine; Chlorprothixene; Fluphenazine; Haloperidol; Humans; Met | 1966 |
N-Methyl-D-aspartate receptor participation in Parkinson's disease, a neurodegenerative disorder.
Topics: Animals; Antiparkinson Agents; Apomorphine; Benzazepines; Catalepsy; Dizocilpine Maleate; Haloperido | 1995 |
Modulation of motor functions involving the dopaminergic system by AT1 receptor antagonist, losartan.
Topics: Angiotensin Receptor Antagonists; Animals; Apomorphine; Benzazepines; Catalepsy; Dopamine; Dopamine | 1998 |
D1/D2 dopamine and N-methyl-D-aspartate (NMDA) receptor participation in experimental catalepsy in rats.
Topics: Animals; Benzazepines; Catalepsy; Dizocilpine Maleate; Dopamine D2 Receptor Antagonists; Drug Intera | 1992 |
Modulation of various central neurotransmitter systems and perphenazine-induced catalepsy in rats.
Topics: Animals; Antiparkinson Agents; Brain; Catalepsy; Catecholamines; Hydroxyindoleacetic Acid; Male; Per | 1987 |
Correlation between the duration of perphenazine catalepsy and pressure maintained tonic immobility under the influence of beta-sympathotropic agents.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Behavior, Animal; Catalepsy; Female; | 1989 |
Yohimbine potentiates the anticataleptic action of clonidine against perphenazine-induced catalepsy in rats.
Topics: Animals; Catalepsy; Clonidine; Drug Synergism; Male; Perphenazine; Quipazine; Rats; Rats, Inbred Str | 1986 |
Is there a relationship between the involvement of extrapyramidal and mesolimbic brain areas with the cataleptic action of neuroleptic agents and their clinical antipsychotic effect?
Topics: Animals; Aporphines; Benzoates; Butyrophenones; Catalepsy; Dioxoles; Extrapyramidal Tracts; Humans; | 1973 |
Increased sensitivity to neuroleptics in rats with lesions of the central nervous system.
Topics: Animals; Catalepsy; Central Nervous System; Central Nervous System Diseases; Chlorpromazine; Drug Hy | 1972 |
[Follow-up studies of schizophrenia].
Topics: Adult; Catalepsy; Catatonia; Chlorpromazine; Chronic Disease; Convulsive Therapy; Depersonalization; | 1971 |
[Behavioral and neuopharmacological effects of flupentixol].
Topics: Anesthetics; Animals; Antiemetics; Behavior, Animal; Body Temperature; Catalepsy; Cats; Central Nerv | 1971 |
Pharmacological studies with some newly synthesized phenothiazines exhibiting lesser extrapyramidal reactions.
Topics: Aggression; Amphetamine; Animals; Behavior, Animal; Catalepsy; Central Nervous System; Chemical Phen | 1969 |
The prediction of sedative potency of neuroleptics.
Topics: Animals; Ataxia; Avoidance Learning; Catalepsy; Chlorpromazine; Haloperidol; Humans; Hypnotics and S | 1970 |
The influence of various neuroleptic drugs on noise escape response in rats.
Topics: Animals; Antidepressive Agents; Avoidance Learning; Benperidol; Blepharoptosis; Butyrophenones; Cata | 1970 |
Lesions in corpus striatum and cortex of rat brains and the effect on pharmacologically induced stereotyped, aggressive and cataleptic behaviour.
Topics: Aggression; Animals; Basal Ganglia; Behavior, Animal; Catalepsy; Cerebral Cortex; Dextroamphetamine; | 1970 |
Influence of antiparkinson drugs and amphetamine on some pharmacological effects of phenothiazine derivatives used as neuroleptics.
Topics: Amphetamine; Animals; Apomorphine; Avoidance Learning; Behavior, Animal; Body Temperature; Catalepsy | 1964 |